Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pekka Kurki

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Bioanalysis|January 24, 2019
Compatibility of immunogenicity guidance by the EMA and the US FDAPekka Kurki
Expert Review of Clinical Pharmacology|August 22, 2015
Biosimilar regulation in the EUPekka Kurki, Niklas Ekman
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|July 6, 2005
Differences in product information of biopharmaceuticals in the EU and the USA: implications for product developmentOuti Nieminen, Pekka Kurki, Katrina Nordström
Duodecim; Laaketieteellinen Aikakauskirja|December 16, 2017
New study designs in clinical drug developmentOlli Tenhunen, Miia Turpeinen, Pekka Kurki
Drugs|October 1, 2021
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory PerspectivePekka Kurki, Sean Barry, Ingrid Bourges, et al.
Blood|October 10, 2014
Biosimilars: the science of extrapolationMartina Weise, Pekka Kurki, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2022
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical ExperiencePekka Kurki, Hye-Na Kang, Niklas Ekman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 26, 2017
Interchangeability of Biosimilars: A European PerspectivePekka Kurki, Leon van Aerts, Elena Wolff-Holz, et al.
BMJ Open|October 31, 2019
Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative studyHanna M Tolonen, Marja Sa Airaksinen, Päivi Ruokoniemi, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 16, 2021
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic ReviewHanna M Tolonen, Jenni Falck, Pekka Kurki, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Bioanalysis|January 24, 2019
Compatibility of immunogenicity guidance by the EMA and the US FDAPekka Kurki
Expert Review of Clinical Pharmacology|August 22, 2015
Biosimilar regulation in the EUPekka Kurki, Niklas Ekman
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|July 6, 2005
Differences in product information of biopharmaceuticals in the EU and the USA: implications for product developmentOuti Nieminen, Pekka Kurki, Katrina Nordström
Duodecim; Laaketieteellinen Aikakauskirja|December 16, 2017
New study designs in clinical drug developmentOlli Tenhunen, Miia Turpeinen, Pekka Kurki
Drugs|October 1, 2021
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory PerspectivePekka Kurki, Sean Barry, Ingrid Bourges, et al.
Blood|October 10, 2014
Biosimilars: the science of extrapolationMartina Weise, Pekka Kurki, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2022
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical ExperiencePekka Kurki, Hye-Na Kang, Niklas Ekman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 26, 2017
Interchangeability of Biosimilars: A European PerspectivePekka Kurki, Leon van Aerts, Elena Wolff-Holz, et al.
BMJ Open|October 31, 2019
Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative studyHanna M Tolonen, Marja Sa Airaksinen, Päivi Ruokoniemi, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 16, 2021
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic ReviewHanna M Tolonen, Jenni Falck, Pekka Kurki, et al.
Pageof 2